Insider Buys ATYR Pharma Shares Amid Decline, Betting on Orphan‑Drug Growth
Insider purchase of 72,450 ATYR Pharma shares shows confidence in its orphan‑drug pipeline and potential market rebound ahead of FDA milestones.
4 minutes to read
ATYR PHARMA INC